Skip to content
Menu

B of A Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030

Benzinga Newsdesk 2 weeks ago

Analyst RatingsNewsPrice TargetHot

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

B of A Securities analyst Tazeen Ahmad maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $908 to $1030.

B of A Securities analyst Tazeen Ahmad maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $908 to $1030.

Read at benzinga.com

← All stock news